Disease · MONDO_0006791

hyperemesis gravidarum

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hyperemesis gravidarum. Diseases, record MONDO_0006791. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006791

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hyperemesis gravidarum; Open Targets
Open Targets ID: MONDO_0006791; Open Targets
Other names: hyperemesis gravidarum (disease); Open Targets
MeSH: D006939; MeSH
Highest stage of its drugs: Phase 3, for 1 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CLONIDINE	CHEMBL134	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CAPSAICIN	CHEMBL294199	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
GABAPENTIN	CHEMBL940	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METOCLOPRAMIDE	CHEMBL86	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MIRTAZAPINE	CHEMBL654	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ONDANSETRON	CHEMBL46	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets35

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA2A	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/152	Drugs and targets
HTR3A	5-hydroxytryptamine receptor 3A	2	Serotonin 3a (5-HT3a) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3359	Drugs and targets
CACNA1A	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 2	https://conductscience.org/library/genes/773	Drugs and targets
CACNA1B	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 2	https://conductscience.org/library/genes/774	Drugs and targets
CACNA1C	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 2	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 2	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1E	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 2	https://conductscience.org/library/genes/777	Drugs and targets
CACNA1F	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 2	https://conductscience.org/library/genes/778	Drugs and targets

1 to 10 of 35

See all 35 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02163434	Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum	Phase 2	31	2021-09-27	Hyperemesis Gravidarum	GABAPENTIN, METOCLOPRAMIDE	Its record names the disease	ClinicalTrials.gov
NCT05098067	Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy	Phase 2	30	2024-02-07	Hyperemesis Gravidarum, Nausea Gravidarum, Vomiting of Pregnancy	CAPSAICIN	Its record names the disease	ClinicalTrials.gov
NCT01559012	Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum	Phase 3	13	2014-04-30	Hyperemesis Gravidarum	CLONIDINE	Its record names the disease	ClinicalTrials.gov
NCT03785691	Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum	Phase 2	58		Hyperemesis Gravidarum, Nausea Gravidarum, Vomiting of Pregnancy	MIRTAZAPINE, ONDANSETRON	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Intervention Group vs Placebo Group: deaths from any cause	0 of 15	0 of 15	30	NCT05098067	Trial comparisons
Intervention Group vs Placebo Group: serious adverse events	0 of 15	0 of 15	30	NCT05098067	Trial comparisons
Clonidine vs Placebo: Number of Patients Choosing Active Treatment for Off-label, Compassionate Use.	9 of 12	3 of 12	24	NCT01559012	Trial comparisons
Gabapentin vs Metoclopramide: Percent of Subjects Requiring Repeat iv Hydration or Hospital Admission for HG From the Outpatient Setting.	5 of 12	5 of 9	21	NCT02163434	Trial comparisons
Gabapentin vs Metoclopramide: deaths from any cause	0 of 12	0 of 9	21	NCT02163434	Trial comparisons
Gabapentin vs Metoclopramide: serious adverse events	0 of 12	0 of 9	21	NCT02163434	Trial comparisons
Clonidine vs Placebo: serious adverse events	0 of 6	0 of 7	13	NCT01559012	Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41478546	DERIVED	1	PubMed
37271593	DERIVED	1	PubMed
33451591	DERIVED	1	PubMed
32209630	DERIVED	1	PubMed
24684734	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006791

GET https://conductscience.org/api/diseases/v1/MONDO_0006791/targets?page=2

API reference For AI assistants